Lyme disease, also known as Borreliosis, is an infectious disease caused by the Borrelia burgdorferi bacteria. It is transmitted through the bites of infected blacklegged ticks. If left untreated, infection can spread to joints, the heart, and the nervous system. Common antibiotics are generally effective for treatment of early localized infection. However, treatment of late disseminated infections involves prolonged courses of intravenous antibiotics. The global Lyme disease treatment market is fragmented in nature, with presence of various branded and generic medicines.
The global Lyme Disease Treatment Market is estimated to be valued at US$ 1.56 Bn in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity
Increasing Lyme Disease Prevalence
Lyme disease prevalence has been rising significantly across various countries worldwide in the recent past. According to Centers for Disease Control and Prevention (CDC), around 476,000 Americans are estimated to get Lyme disease each year, making it a serious public health concern for the country. This rising Lyme disease prevalence poses a massive opportunity for the lyme disease treatment market players to boost their product sales and revenue through increased adoption of therapeutic drugs and vaccines in the coming years. With no improvements made in diagnostic tools and vaccines, increased investments in R&D for advanced therapies is expected for lyme disease treatment market players to capitalize on this opportunity.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate as it requires huge investments for R&D and clinical trials for new drugs. However, some biotech startups are emerging.
Bargaining power of buyers: The bargaining power of buyers is high as treatments mostly come from a few pharmaceutical companies. Buyers can negotiate on price.
Bargaining power of suppliers: The bargaining power of suppliers is moderate as suppliers of raw materials include generic drug makers. Suppliers have some control over prices.
Threat of new substitutes: The threat of substitutes is low as there are limited treatment options for Lyme disease currently. Alternate treatments include antibiotics or alternative medicine.
Competitive rivalry: The competitive rivalry is high among major players like Pfizer, GlaxoSmithKline, and Merck & Co. Companies compete on pricing, partnerships, and new drug launches.
SWOT Analysis
Strength: The growing incidence of Lyme disease across regions provides opportunities. Further, rising awareness favorably impacts the market.
Weakness: Lyme disease remains underreported in many regions. Also, limited treatment options and resistance to certain antibiotics pose challenges.
Opportunity: Emerging biotech startups are exploring new drug candidates and treatment approaches. Favorable regulatory environment boosts product approvals.
Threats: Expensive R&D for new drugs and diagnostic tests is a major deterrent. Delayed diagnosis also affects treatment outcomes and market expansion.
Key Takeaways
The Global Lyme Disease Treatment Market Growth is expected to witness high over the forecast period driven by the increasing prevalence worldwide. The market size is projected to reach nearly US$ 2.3 Bn by 2030.
Regional analysis indicates North America dominates currently due to growing Lyme disease burden in the US and Canada. Europe also captures significant share with rising cases year-over-year. However, Asia Pacific is expected to grow at the fastest pace due to improving diagnostic rates.
Key players operating in the Lyme disease treatment market are Pfizer, GlaxoSmithKline, and Merck & Co. Companies compete on pricing, partnerships, and new drug launches such as Pfizer's Lyntix. Emerging players like Valneva are exploring novel vaccines while Enzo Biochem focuses on diagnostic tests.
Explore more information on this topic, Please visit-
Explore more trending article on this topic:
